| Arbor Trail Rehab And Skilled Nursing Center | |
| 611 Turner Camp Rd, Inverness, Florida 34453 | |
| (352) 637-1130 | |
| Name | Arbor Trail Rehab And Skilled Nursing Center |
|---|---|
| Location | 611 Turner Camp Rd, Inverness, Florida |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 116 |
| Occupancy Rate | 73.79% |
| Medicare ID (CCN) | 105703 |
| Legal Business Name | Sovereign Healthcare Of Inverness, Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1760479380 |
| Organization Name | SOVEREIGN HEALTHCARE OF INVERNESS, LLC |
| Doing Business As | ARBOR TRAIL REHAB & SKILLED NURSING CENTER |
| Address | 611 Turner Camp Rd, Inverness, FL 34453 |
| Phone Number | 352-637-1130 |
News Archive
Toshiba Corporation and a team led by Professor Yozo Nakazawa at the Department of Pediatrics, Shinshu University, have together developed a "tumor-tropic liposome technology" for gene therapy. The technology uses unique, nano-sized biodegradable liposomes developed by Toshiba to accurately and efficiently deliver therapeutic genes to targeted cancer cells, and achieves safer gene delivery than viruses used as carriers.
Alvine Pharmaceuticals, Inc. today announced the presentation of data from a Phase 2A trial of its lead compound, ALV003, at the 2012 Digestive Diseases Week (DDW) meeting held in San Diego, California. The study results met the primary endpoint of demonstrating that oral ALV003, administered in the context of a gluten free diet (GFD), can diminish gluten-induced intestinal mucosal injury in well-controlled celiac disease patients. The company plans to initiate a Phase 2B trial later this year.
Blue light can both set the mood and set in motion important biological responses. Researchers at the University of Pennsylvania's School of Medicine and School of Arts and Sciences have teased apart the separate biological responses of the human eye to blue light, revealing an unexpected contest for control.
In the U.S., someone suffers a heart attack every 34 seconds - their heart is starved of oxygen and suffers irreparable damage. Engineering new heart tissue in the laboratory that could eventually be implanted into patients could help, and scientists are reporting a promising approach tested with rat cells.
› Verified 8 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Toshiba Corporation and a team led by Professor Yozo Nakazawa at the Department of Pediatrics, Shinshu University, have together developed a "tumor-tropic liposome technology" for gene therapy. The technology uses unique, nano-sized biodegradable liposomes developed by Toshiba to accurately and efficiently deliver therapeutic genes to targeted cancer cells, and achieves safer gene delivery than viruses used as carriers.
Alvine Pharmaceuticals, Inc. today announced the presentation of data from a Phase 2A trial of its lead compound, ALV003, at the 2012 Digestive Diseases Week (DDW) meeting held in San Diego, California. The study results met the primary endpoint of demonstrating that oral ALV003, administered in the context of a gluten free diet (GFD), can diminish gluten-induced intestinal mucosal injury in well-controlled celiac disease patients. The company plans to initiate a Phase 2B trial later this year.
Blue light can both set the mood and set in motion important biological responses. Researchers at the University of Pennsylvania's School of Medicine and School of Arts and Sciences have teased apart the separate biological responses of the human eye to blue light, revealing an unexpected contest for control.
In the U.S., someone suffers a heart attack every 34 seconds - their heart is starved of oxygen and suffers irreparable damage. Engineering new heart tissue in the laboratory that could eventually be implanted into patients could help, and scientists are reporting a promising approach tested with rat cells.
› Verified 8 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 2 |
| Total Amount of Fines in Dollars | $23377 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 2 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 21.25 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 10.53 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 48.48 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.3 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.48 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0.4 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.84 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 99.26 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 8.59 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 97.9 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.74 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 36.04 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 14 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 16.77 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.74 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 72.86 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 94.34 | 82.93 |
News Archive
Toshiba Corporation and a team led by Professor Yozo Nakazawa at the Department of Pediatrics, Shinshu University, have together developed a "tumor-tropic liposome technology" for gene therapy. The technology uses unique, nano-sized biodegradable liposomes developed by Toshiba to accurately and efficiently deliver therapeutic genes to targeted cancer cells, and achieves safer gene delivery than viruses used as carriers.
Alvine Pharmaceuticals, Inc. today announced the presentation of data from a Phase 2A trial of its lead compound, ALV003, at the 2012 Digestive Diseases Week (DDW) meeting held in San Diego, California. The study results met the primary endpoint of demonstrating that oral ALV003, administered in the context of a gluten free diet (GFD), can diminish gluten-induced intestinal mucosal injury in well-controlled celiac disease patients. The company plans to initiate a Phase 2B trial later this year.
Blue light can both set the mood and set in motion important biological responses. Researchers at the University of Pennsylvania's School of Medicine and School of Arts and Sciences have teased apart the separate biological responses of the human eye to blue light, revealing an unexpected contest for control.
In the U.S., someone suffers a heart attack every 34 seconds - their heart is starved of oxygen and suffers irreparable damage. Engineering new heart tissue in the laboratory that could eventually be implanted into patients could help, and scientists are reporting a promising approach tested with rat cells.
› Verified 8 days ago
Arbor Trail Rehab And Skilled Nursing Center Location: 611 Turner Camp Rd, Inverness, Florida 34453 Phone: (352) 637-1130 | |
Citrus Health And Rehabilitation Center Location: 701 Medical Court East, Inverness, Florida 34452 Phone: (352) 860-0200 |